New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered ...
52-week follow-up data from type 1 diabetes (“T1D”) patients in COVALENT-112 who completed ≥80% of protocol-specified dosing with the read-out expected in the second quarter of 2026. 26-week primary ...
Vanish Skincare's nanofiber dry-fiber delivery format, barrier repair ingredient research, and published guarantee conditions examined for consumers researching acne mask options in 2026.
Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Mawer Investment Management Ltd, dated 11 March ...
The achievement reflects the steady growth of the program since its launch in 2016, bringing the cumulative number of kidneys paired transplants performed under the program to 691 by the end of 2025, ...
In May 2025, Barinthus Bio presented data from two Phase 2 clinical trials of VTP-300 in CHB at the European Association for the Study of the Liver (“EASL”) Congress 2025 showing VTP-300 induced ...
“This report reflects the real burden of living with bladder cancer and the lasting impact of recurrence,” said Meri-Margaret Deoudes, Chief Executive Officer of BCAN. “We thank UroGen for supporting ...
Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive ...
Excellence in Quality and Outcomes (EQO) Program establishes a shared-data, partnership-driven approach to improving health outcomes ...
Reconstructed Ancestors is the first and only feature of its kind, using your DNA and the DNA of close relatives in your family tree who have tested, to predict the ancestry composition of your ...
WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today released a new CEO Corner segment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results